Indications

  • For the treatment of patients with unresectable thyroid cancer.
  • In combination with pembrolizumab, for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
  • In combination with everolimus, for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior antiangiogenic therapy.
  • For the treatment of patients with hepatocellular carcinoma (HCC).
  • In combination with pembrolizumab, for the treatment of patients with advanced endometrial carcinoma (EC) who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.

Disclaimer

This website is intended for healthcare professionals only. To proceed, please indicate your PRC (Professional Regulation Commission) number for verification purposes.

By clicking "Continue," you consent to the collection and use of your PRC number and any other personal data provided for the purpose of confirming your professional credentials and accessing restricted content in this site. Your data will be handled in accordance with our Data Privacy Policy and applicable data protection laws.

If you do not consent to these terms, please exit the site.

Oops! We could not locate your form.